Subscribe
shutterstock_1349383838_thomas_quack
Thomas Quack / Shutterstock.com
22 October 2019AmericasSarah Morgan

CRISPR Therapeutics to buy JV from Bayer

A joint venture between gene-editing startup CRISPR Therapeutics and German pharmaceutical company Bayer will come under the control of CRISPR Therapeutics, according to the pair’s proposed plans.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Bayer and CRISPR close joint venture transaction
19 August 2016   Bayer has launched a partnership with CRISPR Therapeutics.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

More on this story

Americas
Bayer and CRISPR close joint venture transaction
19 August 2016   Bayer has launched a partnership with CRISPR Therapeutics.

More on this story

Americas
Bayer and CRISPR close joint venture transaction
19 August 2016   Bayer has launched a partnership with CRISPR Therapeutics.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility